NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway

Xianxiu Ge1, Youli Wang, Quanpeng Li

  • 1Institute of Digestive Endoscopy and Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China.

Oncology Reports
|April 27, 2013
PubMed

Insights

NK4 enhances 5-fluorouracil (5-FU) induced apoptosis in cholangiocarcinoma (CCA) cells by activating the mitochondrial pathway. This suggests NK4 may be crucial for 5-FU efficacy, while its downregulation can lead to drug resistance.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Cholangiocarcinoma (CCA) is a challenging cancer with limited treatment options.
  • Hepatocyte growth factor (HGF) and its receptor Met play roles in cancer progression.
  • NK4, an antagonist of HGF/Met signaling, is being investigated for its therapeutic potential.

Purpose of the Study:

  • To investigate the role of NK4 in modulating cholangiocarcinoma cell response to 5-fluorouracil (5-FU).
  • To explore the mechanisms by which NK4 affects 5-FU-induced cell death.
  • To determine if NK4 influences 5-FU metabolism or intracellular signaling pathways.

Main Methods:

  • Established a CCA cell line (HuCC-T1) engineered to overexpress NK4 (Hu-NK4).
  • Assessed cell proliferation, cell cycle distribution, and apoptosis.
  • Analyzed mRNA levels of key 5-FU metabolism enzymes and western blot for signaling pathway components (caspases, Bcl-2 family, Met phosphorylation).

Main Results:

  • NK4 expression did not significantly alter 5-FU metabolism or cell cycle distribution.
  • 5-FU-induced apoptosis was significantly enhanced in Hu-NK4 cells compared to controls.
  • NK4 potentiated 5-FU-induced activation of caspase-3 and caspase-9, linked to the intrinsic mitochondrial pathway and Bcl-2 family modulation.

Conclusions:

  • NK4 acts as a mediator of 5-FU-induced apoptosis in CCA cells, primarily through the intrinsic mitochondrial pathway.
  • NK4 enhances the efficacy of 5-FU by promoting cancer cell death.
  • Downregulation of NK4 in response to 5-FU may contribute to intrinsic drug resistance in CCA.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...